Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Expected to Post Earnings of -$0.66 Per Share

Analysts forecast that Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) will announce ($0.66) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Six analysts have made estimates for Aerie Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.77) and the highest is ($0.61). Aerie Pharmaceuticals posted earnings of ($0.83) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 20.5%. The company is expected to issue its next earnings report on Thursday, August 5th.

On average, analysts expect that Aerie Pharmaceuticals will report full-year earnings of ($2.49) per share for the current fiscal year, with EPS estimates ranging from ($2.82) to ($2.21). For the next fiscal year, analysts expect that the company will post earnings of ($1.36) per share, with EPS estimates ranging from ($1.94) to ($0.79). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Aerie Pharmaceuticals.

Aerie Pharmaceuticals (NASDAQ:AERI) last issued its quarterly earnings data on Tuesday, May 4th. The company reported ($0.72) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.69) by ($0.03). The company had revenue of $22.97 million for the quarter, compared to the consensus estimate of $23.35 million. Aerie Pharmaceuticals had a negative net margin of 205.13% and a negative return on equity of 337.04%.

Several research analysts have weighed in on AERI shares. Needham & Company LLC started coverage on shares of Aerie Pharmaceuticals in a research report on Friday, April 30th. They issued a “buy” rating and a $26.00 price target on the stock. HC Wainwright reiterated a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Monday, March 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company’s stock. Aerie Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $22.63.

AERI opened at $15.56 on Tuesday. The company has a quick ratio of 2.84, a current ratio of 3.14 and a debt-to-equity ratio of 8.78. Aerie Pharmaceuticals has a 1-year low of $9.01 and a 1-year high of $21.30. The company has a market capitalization of $729.66 million, a P/E ratio of -4.07 and a beta of 0.72. The stock has a 50 day simple moving average of $17.22.

Hedge funds have recently made changes to their positions in the company. Global Retirement Partners LLC raised its position in shares of Aerie Pharmaceuticals by 101.5% during the 1st quarter. Global Retirement Partners LLC now owns 1,666 shares of the company’s stock valued at $30,000 after purchasing an additional 839 shares during the period. US Bancorp DE raised its position in shares of Aerie Pharmaceuticals by 66.7% during the 4th quarter. US Bancorp DE now owns 2,184 shares of the company’s stock valued at $30,000 after purchasing an additional 874 shares during the period. Quantbot Technologies LP bought a new stake in shares of Aerie Pharmaceuticals during the 1st quarter valued at $59,000. Royal Bank of Canada raised its position in shares of Aerie Pharmaceuticals by 45.2% during the 1st quarter. Royal Bank of Canada now owns 3,461 shares of the company’s stock valued at $61,000 after purchasing an additional 1,077 shares during the period. Finally, Montag A & Associates Inc. bought a new stake in shares of Aerie Pharmaceuticals during the 4th quarter valued at $104,000. Hedge funds and other institutional investors own 98.86% of the company’s stock.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma.

Featured Article: The Discount Rate – What You Need to Know

Get a free copy of the Zacks research report on Aerie Pharmaceuticals (AERI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.